Drugs.com - New Drug Approvals

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel)...

Apr 29, 2025 - 23:51
 0
FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel)...
Read More

Tags:

Previous Article

Booking Exec Says We're 'Agnostic' on Canadians Picking Mexico Over the U.S.

Next Article

Chanel’s love letter to Italy at Lago di Como cruise show

Related Posts

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

FDA Approves Omlyclo (omalizumab-igec), an Interchangea...

Apr 26, 2025  0

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

Novartis Receives Third FDA Approval for Oral Fabhalta ...

Apr 26, 2025  0

FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy

FDA Grants Accelerated Approval for Vanrafia (atrasenta...

Apr 26, 2025  0